Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age
As one of the fastest growing cities in America, Seattle stands out as a pivotal location for clinical research. Home to an extensive healthcare network and prominent research institutions, Seattle offers innovative approaches to clinical research and a significant contribution to medical science.
Leading centers such as the Fred Hutchinson Cancer Research Center, the University of Washington Medical Center, and the Seattle Children's Research Institute are at the forefront of groundbreaking studies.
Want a closer look at research in Seattle? Read our guide: Clinical Trials in Seattle: Where to Find Studies Near You
Why choose Seattle for clinical trials?
For those considering participating in a clinical trial, there are several reasons why Seattle is a prime choice. The city is home to a robust network of leading research institutions, which are known for their pioneering work and advanced medical research. Seattle’s collaborative environment and emphasis on innovation enhance the quality and impact of clinical studies.
By participating in a clinical trial in Seattle, you gain access to some of the most advanced research and treatments available, while also contributing to significant medical discoveries. The city's commitment to cutting-edge science and a supportive research infrastructure make it an ideal location for advancing medical knowledge and improving future healthcare outcomes.
Common conditions studied in Seattle
Seattle's reputation as a hub for clinical research is supported by its world-class research institutions and a collaborative healthcare community studying a wide range of medical conditions.
Cancer
Seattle is a leader in cancer research, with institutions such as the Fred Hutchinson Cancer Research Center and the Seattle Cancer Care Alliance at the forefront. As the leading cause of death in the wider state of Washington, research here focuses on cutting-edge areas such as immunotherapy and personalized medicine.
Trials explore innovative treatments like CAR-T cell therapy, which modifies a patient’s own immune cells to target cancer, and novel drug combinations designed to overcome resistance to existing therapies. These efforts aim to improve survival rates and quality of life for cancer patients.
Neurological disorders
Seattle’s expertise in neurological research is reflected by institutions like the University of Washington’s Alzheimer’s Disease Research Center and the Allen Institute for Brain Science.
Clinical trials in this area delve into understanding the molecular and genetic underpinnings of neurodegenerative diseases. For instance, research on Alzheimer’s disease includes trials investigating potential disease-modifying drugs and advanced imaging techniques to detect early signs of cognitive decline. Similarly, studies on Parkinson’s disease and multiple sclerosis (MS) focus on new therapies that could slow disease progression or improve symptoms.
Infectious diseases
The city’s global health focus is evident in its research on infectious diseases. Institutions like the Fred Hutchinson Cancer Research Center and the University of Washington conduct trials on diseases such as HIV/AIDS, tuberculosis, and emerging pathogens like COVID-19.
Research here includes developing new vaccines, testing antiviral therapies, and exploring novel strategies for disease prevention and management. Seattle’s role in infectious disease research is bolstered by its commitment to global health and its response to emerging health threats.
Autoimmune disorders
Seattle’s research into autoimmune diseases such as rheumatoid arthritis, prurigo nodularis and lupus is conducted at leading institutions like the Fred Hutchinson Cancer Research Center and the University of Washington. Clinical trials explore new treatments aimed at modulating the immune system to reduce inflammation and damage associated with autoimmune conditions.
Metabolic disorders
Clinical trials in Seattle also address metabolic disorders, including diabetes and obesity. The city’s research focuses on innovative approaches such as new medications, metabolic monitoring technologies, and lifestyle interventions designed to improve metabolic health. Studies investigate ways to better manage blood sugar levels, reduce obesity-related complications, and understand the metabolic pathways involved in these conditions.
Cardiovascular diseases
Seattle’s research institutions, including the Swedish Medical Center and the University of Washington, are heavily involved in trials related to cardiovascular health. With heart disease being a leading cause of death in the state, these studies often focus on heart failure, coronary artery disease, and hypertension.
Current research includes evaluating the efficacy of new medications designed to manage heart failure, innovative interventional procedures such as catheter-based treatments, and lifestyle interventions aimed at preventing cardiovascular disease. Seattle’s emphasis on heart health is supported by its strong network of cardiologists and researchers dedicated to improving patient outcomes.
Local regulations and guidelines
In Seattle, clinical trials are rigorously regulated by a combination of federal, state, and local guidelines, ensuring ethical and scientific integrity. Federal oversight is provided by the FDA, which enforces Good Clinical Practice (GCP) standards, and the Office for Human Research Protections (OHRP), which mandates Institutional Review Board (IRB) review and participant protection.
At the state level, the Washington State Department of Health oversees compliance with health regulations, while local IRBs provide additional scrutiny and oversight. Local research institutions and networks further uphold these standards, providing a well-regulated environment that supports innovative and responsible clinical research.
Benefits of participating in clinical trials
Participating in a clinical trial offers a unique chance to access cutting-edge treatments and therapies in the early stages of development and before they are widely available. Participants also benefit from exceptional care provided by top healthcare professionals, who ensure personalized attention and rigorous monitoring throughout the study.
Being involved in clinical trials is crucial for advancing medical research, often leading to significant progress in treatment and prevention for various conditions. By taking part, individuals not only access groundbreaking medical options early but also play a vital role in expanding scientific knowledge, ultimately improving healthcare outcomes for future patients.
Interested in participating in clinical trials but worried about how long they might take? Check out our comprehensive guide for all the information you need to make an informed decision.
How to enroll in a clinical trial in Seattle
Enrolling in a clinical trial through our platform is a straightforward and user-friendly process. Here's how to get started:
- Identify your trial: Use our intuitive search bar or filter options to locate clinical trials specific to requirements. This first step simplifies the process of finding relevant research studies tailored to your needs.
- Select your preferred location: To find trials conveniently located near you, simply input your preferred location into the dedicated filter bar on the left-hand side of the page.
- Explore study details: For in-depth information about each study, simply click the “Learn More” button. This will provide you with comprehensive details about the trial, including objectives, procedures, and eligibility criteria.
- Complete the health profile: After clicking on the “Get started” button you will be taken to our efficient 5-step application process to provide important health information. This helps us match you with the clinical trial that best fits your needs.
- Submit the application: After completing the application, send it in. A clinical trial coordinator will review it and contact you regarding the possibility of participation.